Computational Analysis of FDA-Approved Drugs for Potential Repurposing in Alzheimer’s Disease: Targeting mTOR and NGFR Pathways. Sci. Ess. J. 2026;42(1):50-70. doi:10.69523/sej.2026.42.17130